Clinical trials: Advanced Prostate Carcinoma
Prostate Cancer, Advanced Renal Cell Carcinoma
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma.
- Conditions
- Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
- Trial name
- NCT02735252
- Testing
- Systemic therapy, StrataNGS
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
This clinical study will evaluate the role of combination therapy of docetaxel followed by Provenge for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793765
- Testing
- Docetaxel, Sipuleucel-T
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04927663
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
Advanced Prostate Cancer
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with…
- Trial name
- TRIPTOCARE LT (NCT01383863)
- Where
- 35 sites in Denmark, France and 5 more
- Volunteers
- 180 people
- Sponsor
- Ipsen
Prostate Cancer
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
- Trial name
- NCT06139575
- Testing
- Lutetium Lu 177 JH020002 Injection
- Where
- 13 sites in China
- Volunteers
- 90 people
- Sponsor
- Bivision Pharmaceuticals, Inc.
Melanoma Stage IV, Sarcoma
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.
- Conditions
- Melanoma Stage IV, Sarcoma, Squamous Cell Carcinoma, Pancreatic Cancer Stage IV
- Trial name
- HSP70CTC (NCT04628806)
- Testing
- CTC isolation by HSP70
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Charite University, Berlin, Germany
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited…
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Trial name
- SPARKLE (NCT07650240)
- Testing
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT04134260
- Testing
- Apalutamide, Biospecimen Collection, Bone Scan
- Where
- 350 sites in United States, Canada
- Volunteers
- 586 people
- Sponsor
- NRG Oncology
Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
This phase II trial tests how well bright white light (BWL) therapy works in reducing cancer-related fatigue and depression in patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph…
- Conditions
- Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT05869682
- Testing
- Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- City of Hope Medical Center
Advanced and/or Metastatic Solid Tumours
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours.
- Trial name
- NCT05836623
- Testing
- Radiolabelled CB307, CB307
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Crescendo Biologics Ltd.
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and…
- Conditions
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma, Locally Advanced Prostate Cancer, Unfavourable Intermediate Risk Prostate Cancer
- Trial name
- DAPROCA10 (NCT07343349)
- Testing
- Addition of focal boost and hypofractionation
- Where
- 3 sites in Denmark
- Volunteers
- 1,016 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Stage III Prostate Cancer, Stage IIIA Prostate Cancer
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
This phase I trial studies the side effects of anti-PD-1 monoclonal antibody REGN2810 (REGN2810) and/or ipilimumab when given together with stereotactic body radiation therapy before surgery in treating participants with prostate…
- Conditions
- Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer
- Trial name
- NCT03477864
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Neoplasms, Lung Neoplasms
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to…
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms
- Trial name
- N1 (NCT02900248)
- Testing
- Provider determined
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CureOne
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center